This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
What's in the Cards for HCA Healthcare (HCA) in Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to be aided by strong revenues, driven by higher admissions.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Anthem (ANTM) Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Anthem (ANTM) is likely to continue with its winning streak in the third quarter, backed by its Government Business as well as Commercial & Specialty Business segments.
Why Amgen (AMGN) Might Surprise This Earnings Season
by Zacks Equity Research
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $188.10, moving +0.12% from the previous trading session.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q3 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Can Amgen (AMGN) Keep the Earnings Streak Alive in Q3?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMGN) Outperforming Other Medical Stocks This Year?
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.
Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings?
by Zacks Equity Research
While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
What's in Store for Celgene Corp. (CELG) Q3 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and other pipeline updates when Celgene (CELG) reports Q3 results on Oct 25.
Amgen (AMGN) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Let's look at the factors that will impact Alexion's (ALXN) third -quarter 2018 earnings scheduled to release on Oct 24.
Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?
by Zacks Equity Research
Anika Therapeutics (ANIK) is scheduled to report third-quarter earnings on Oct 24.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $201.80, moving -0.45% from the previous trading session.